BridgeBio Pharma is continuing the launch of Attruby while advancing three drug candidates that could potentially reach the market within the next 12 months. The company said it expects its next launch could be BBP-418, a glycosylation substrate designed to restore muscle function that is awaiting an FDA decision in November as a potential treatment for a form of limb-girdle muscular dystrophy.
The company is also developing encaleret for autosomal dominant hypocalcemia, a calcium deficiency disorder, and infigratinib, an oral treatment for children with achondroplasia, being developed in partnership with Kyowa Kirin. BridgeBio has reported successful phase 3 results for both programs. Cantor analyst Josh Schimmer has estimated that infigratinib has an annual sales potential of $2 billion, while analysts at William Blair have described BBP-418 as a potential blockbuster.
BridgeBio is already generating sales from Attruby, its ATTR-CM medicine. In its most recent quarterly report, the company reported Attruby sales of $181 million during the first three months of 2026. The treatment was approved in November 2024 and generated $362 million in sales during its first four full quarters on the market.
As the company continues the commercialization of Attruby and prepares for potential future launches, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in newly issued convertible preferred equity.
Commenting on the transaction, BridgeBio co-founder and Chief Executive Officer Neil Kumar said, “Access to this type and quantum of capital ensures we can deliver on the promise of our launching medicines and beyond.”
Under the terms announced on July 1, the financing carries an initial dividend of 7% and an initial conversion price of $137.79 per share. BridgeBio said this conversion price represents a premium of more than 100% compared with the company’s 30-day average share price. After five years, the conversion price will increase to $153.10 per share, which the company said represents a premium of more than 125%.
Sixth Street is providing $800 million of the investment, while HealthCare Royalty is contributing $134 million. BridgeBio said additional details regarding the transaction would be disclosed in a securities filing that had not yet been posted by mid-morning on Wednesday.
The company stated that the financing is intended to support its current and upcoming product launches. Analysts at Leerink suggested that BridgeBio could also be considering merger and acquisition opportunities, citing the size of the financing, the company’s existing balance sheet strength, and the potential value of three priority review vouchers that could result from FDA approvals of its leading pipeline candidates, which target genetic disorders with unmet need.
In a note to investors, Leerink stated that the financing, combined with the company’s financial position and the possible value of the vouchers, suggested BridgeBio may be accumulating additional capital resources. The analysts also described the transaction as incrementally positive, noting that the conversion premium provides long-term capital with limited dilution ahead of what they called a catalyst-rich year.
BridgeBio’s share price was $74.55 on Wednesday morning, up 14% over the previous month.
BridgeBio is strengthening its position in the biotechnology industry by accelerating the commercial launch of Attruby, advancing three late-stage drug development programs, and securing new investment to support future growth. The latest funding provides BridgeBio with additional financial flexibility as it continues to expand its pipeline of innovative therapies for patients with serious genetic diseases.
The company’s strategy combines commercial execution with continued investment in research and development, allowing BridgeBio to pursue multiple high-value programs while preparing for future regulatory milestones.
BridgeBio Accelerates the Attruby Launch
The successful launch of Attruby represents an important milestone for BridgeBio as the company transitions from a research-focused biotechnology organization into a commercial-stage biopharmaceutical company. Resources from the recent investment are expected to support product commercialization, physician education, patient access initiatives, and market expansion.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
